oncology-therpeutics-2017-scientifictracks

26 / 28

Page 48
Notes:
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
The Effect of the Anti-Cancer Preparation NSC-631570 on Prostate Cancer
Wassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
U nusual for an anticancer agent NSC 631570 possesses
some distinct immune properties. In several immune
target-effector systems NSC 631570 significantly amplified
the malignotoxic activity of macrophages, lymphocytes and
NK cells, and stimulates dendritic cells maturation in vitro.
While the parameters like B-lymphocytes count, immune
globulin concentrations, complement and acute phase
proteins did not changed significantly, it can be postulated
NSC 631570 modulates the cellular part of the immune
system whereas the humoral part remains unaffected.
Besides, the NSC631570 has a selective effect – thus, it kills
only cancer cells and the healthy cells remain undamaged.
First indications on the selective effect of NSC 631570 on the
cancer cells were provided in an early study when different
oxygen consumption by normal liver cells and Ehrlich’s
tumor ascitic cells after the incubation with NSC 631570
was revealed. A radio protective effect was found in normal
human fibroblasts. NSC 631570 caused the accumulation
of prostate cancer cells as well as epidermoid carcinoma
cells in the G2/M phase, however, not of normal cells.
The efficacy of NSC-631570 in prostate cancer has been
confirmed in a controlled clinical study. In the study patients,
all standard treatment modalities had been exhausted. The
cancer relapsed and/or progressed and no therapy protocol
was available. The patients were treated with NSC-631570
and partially with local hyperthermia. Following results
were achieved: full remission in 54 patients (73%), partial
remission in 16 patients (22%). Only in 4 patients (5%) the
therapy did not affect the course of the disease.
Speaker Biography
Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and
President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study
at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end
of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in
Austria in 1975. He became the very first scientist in the development of the anticancer
protonic therapy and is the inventor of the preparation against cancer with a selective
effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer
cells are more negative charged than normal cells and invented the Celandine alkaloid
with a positive charge thanks to which it accumulates in cancer cells very fast. He has
received the award for merits of National guild of pharmasists of America. The award
of Austrian Society of sanitary, hygiene and public health services and others.
Total Number of
Patients
Full Remission Partial Remission Disease Progression
74 54 16 4
100% 73% 22% 5%
e: